The Gut-Brain Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-15

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out if transplant of fecal matter (stool), also known as fecal microbiota transplantation (FMT), from a healthy person into the intestines of children and young adults with Autism Spectrum Disorder (ASD).

For this study children between the ages of 5-17years will be recruited over 2 years. Children will be recruited who receive an ASD diagnosis using the gold-standard Autism Diagnosis Observation Schedule -2 (ADOS-2) using module 1, 2 or 3 (none, limited or no moderate expressive language). Children diagnosed with these modules of the ADOS-2 may be at greater risk for GI disorders and rigid-compulsive behaviors. Additional assessment of rigid-compulsive behaviors and social communication will be done using the Repetitive Behavioral Scales-Revised (RBS-R) and Social Responsiveness Scale-2 (SRS-2), respectively. KBIT (the Kaufman Brief Intelligence Test) is used at baseline to obtain patient IQ. Total evaluation time is approximately 90 minutes. Following baseline symptom evaluation, a medical exam will be performed to determine whether each child is expressing specific GI symptoms. In addition, parents will fill out the Questionnaire for Pediatric Gastrointestinal Symptoms- Rome III (QPGS-III). Once an ASD diagnosis is confirmed, FMT treatment will be initiated, which typically occurs within 4-6 weeks of the initial diagnosis. Half 50% of the children (n=5) will receive the equivalent of 50 g of stools from a healthy donor into the jejunum through upper endoscopy and the other 50% off children (n=5) will receive Saline solution as Placebo control through upper endoscopy.

Subjects will have a total of 5 visits within 24 weeks including phone call follow up on Day 7 after FMT.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intestinal Dysbiosis and BBB Integrity in Autism

NCT04321915

Autism Spectrum Disorder

RECRUITING NA

Intestinal Inflammation and Carbohydrate Digestion in Autistic Children

NCT00227487

Autism Inflammation

UNKNOWN NA

Efficacy and Safety of FMT for the Treatment of IBS-D and Mental Health Comorbidity in Young Adults

NCT06297421

Irritable Bowel Syndrome With Diarrhea Fecal Microbiota Transplantation Mental Health Issue

NOT_YET_RECRUITING PHASE2

Assessing the Gut Microbiome and Its Association With Pediatric Stress and Cognition

NCT06269614

Autism Spectrum Disorder Adverse Childhood Experiences Stress Reaction

ACTIVE_NOT_RECRUITING NA

Effect of Fecal Microbiota Transplantation (FMT) in Pediatric Functional Gastrointestinal Disorders

NCT05753774

Functional Gastrointestinal Disorders

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Nearly 1 in 60 children are diagnosed with ASD, a dramatic increase from the start of the 21st century. Although most children with ASD exhibit core social communication deficits, very limited interests, repetitive behaviors and sensory problems, the severity of symptoms and how well each child responds to standard behavioral therapies can vary tremendously from patient to patient. This makes it difficult to enact effective interventions. Other variables also influence the outcomes for ASD patients, including age at first diagnosis, access to care, the quality of treatments and the expertise of interventionists.

Children with ASD also have medical disturbances, which affects their quality of life and compliance in intervention programs. For example, approximately 40 percent of children with ASD have gastrointestinal disturbances (GIDs). Genetics plays a substantial role in risk, but scientists also have determined that non-heritable factors can trigger the expression and severity of ASD symptoms. Clinical research studies from PI laboratories have focused on the gut-brain link that influences ASD symptoms, how a child functions and even responds to interventions .

The investigators hypothesize that children with ASD will tolerate single endoscopic delivery of fecal transplant therapy which will modify their gut microbial profile leading to reduction of repetitive and rigid-compulsive behaviors, based on the Repetitive Behavioral Scales-Revised (RBS-R). Secondary outcomes include improved score in social responsiveness scale and gastrointestinal symptoms . Investigators propose a phase I safety study for the use of FMT in children with Autism Spectrum Disorder.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder (ASD) Gastro-Intestinal Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Placebo Comparator placebo into the jejunum through upper endoscopy.

Group Type PLACEBO_COMPARATOR

FMT versus placebo

Intervention Type BIOLOGICAL

Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.

Other Names:

FMT

Arm 2

Active Comparator: Donor Stool Transplant Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool into the jejunum through upper endoscopy.

Group Type ACTIVE_COMPARATOR

FMT versus placebo

Intervention Type BIOLOGICAL

Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.

Other Names:

FMT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FMT versus placebo

Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.

Other Names:

FMT

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

fecal microbial transplant vs placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 5-17 who have been diagnosed with non-syndromic ASD-s
* Needs upper GI endoscopy
* Clinical Assessment of ASD
* ADOS validated diagnoses of ASD
* Questionnaires: RBS-2 , KBIT, SRS, Rome III Version (QPGS- RIII), Ped QL, SSP

Exclusion Criteria

* Subjects able to give consent/assent but unwilling to give informed consent/assent
* Prematurity (\<36 weeks)
* Pregnancy: testing will be done on FMT day 0 for subjects with childbearing potential
* Subjects with significant renal and liver dysfunction (creatinine \> 2 mg/dl and direct bilirubin \> 2 mg/dl)
* Subjects with congenital or acquired immunodeficiency, or who are immunosuppressed such as neoplastic disease or organ transplantation), have received or are receiving chemotherapy, or have been diagnosed with HIV.
* Subjects with syndromic disorders of defined genetic cause, and subjects who have severe sensory or motor problems (for example, blindness, deafness, seizures, cerebral palsy)
* Subjects with severe food allergies

Minimum Eligible Age

5 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No